1
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mere
3
Communicable disease threats report, 24-30 March 2024, week 13
ECDC
ECDC Communicable Disease Threats Report, 27.03.2024
Tilføjet 27.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 24-30 March 2024 and includes updates on cholera and influenza A(H5N1).
Læs mere
4
Severe Flu Confers Higher Risk for Neuro Disorders vs COVID
Medscape Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Hospitalization for influenza raises the risk for future neurologic conditions more than hospitalization for COVID-19, the results of a large study showed. Medscape Medical News
Læs mere
5
Reporting Protocol for integrated respiratory virus surveillance, version 1.5
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
6
Communicable disease threats report, 10-16 March 2024, week 11
ECDC
ECDC COVID-19 updates, 15.03.2024
Tilføjet 15.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
Læs mere
7
Communicable disease threats report, 10-16 March 2024, week 11
ECDC
ECDC Communicable Disease Threats Report, 15.03.2024
Tilføjet 15.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
Læs mere